Moreover, because the EDN1‐induced paracrine signalling has the potential to support both MITF‐high and AXL‐high phenotypes in acquired resistant tumours, targeting the EDN1‐EDN receptor axis could reduce the complexity seen in patients treated with MAPK inhibitor at time of progression. This evidence concerns the gene MITF and neoplasm.